Oct. 20, 2026 — Who, what, when, where, why: Since mid‑2026, an expanding set of global insurers and large brokerage houses have escalated informal attestations into formal underwriting conditions that specifically require machine‑readable model‑audit reports (MARs) for high‑risk AI and many enterprise placements. The change is now evident in renewal questionnaires, placement checklists and vendor SLAs across financial services, healthcare and regulated technology procurement worldwide. Insurers say MARs give them consistent, verifiable evidence to underwrite AI exposures; enterprises view MARs as a lever for faster placement and, in some cases, lower premiums.

Why this matters now

Three forces continue to collide: wider enterprise deployment of foundation models and large multimodal systems; intensifying regulatory attention (notably the EU AI Act’s high‑risk framework and sectoral guidance in finance and healthcare); and maturation of MLOps tooling that can produce structured audit artifacts. For risk and procurement teams, MARs are increasingly the bridge between engineering controls and commercial insurance economics—without them some underwriters will apply broad exclusions or charge loading for unknown model risk.

What changed since June 2026

  • From encouragement to conditionality. Where MARs were recommended in early 2026, multiple global carriers and leading brokers now list MAR deliverables as explicit prerequisites for binding in high‑exposure accounts. Those requirements appear most often in renewals for financial institutions, large healthcare providers and regulated cloud‑native platforms.
  • Tooling and vendor support deepened. Major MLOps vendors and cloud platforms (for example, established providers’ model registries, CI/CD integrations and telemetry agents) now include export hooks or SDKs that map provenance, test outputs and governance logs into machine‑readable bundles—making MAR generation operationally tractable for enterprise teams.
  • Assurance offerings broadened. Large accounting firms and specialist AI assurance shops expanded MAR‑specific services in 2026, offering scoped attestations that insurers will accept when paired with machine‑readable artifacts and evidence chains.
  • Convergence, not standardization. Industry working groups and consortia have narrowed expected MAR elements—provenance hashes, test‑suite specifications, role‑based access logs and runtime monitoring hooks—even as multiple competing schemas persist. Expect continued convergence toward a small set of common fields rather than a single governing standard this year.

Concrete MAR elements insurers now ask for

Underwriters and brokers are moving beyond narrative attestations to request verifiable, machine‑readable artifacts. Typical elements now requested include:

  • Structured model metadata: model identifier, architecture, training and last‑retrain timestamps, dataset references or dataset‑ID pointers, and cryptographic provenance (hashes or signed receipts) where available.
  • Test suite and results: standardized validation metrics, adversarial/robustness test outputs, fairness and bias measurements, and the exact test specifications used (versioned and machine readable).
  • Governance and controls logs: deployment gating records, role‑based access control (RBAC) audit trails, CI/CD pipeline signatures, release approvals and incident escalation records.
  • Runtime telemetry and explainability hooks: production monitoring snapshots, model drift signals, and explainability artifacts or request/response logging sufficient to reproduce a claim‑period behavior sample.
  • Assurance artifacts: third‑party attestations with a defined scope, evidence chain and signatures; retention policy statements (commonly aligned to 5–7 years for business‑critical models).

Real‑world signals and examples

Procurement and risk teams in banking and healthcare report that renewals in Q3–Q4 2026 often included MAR deliverable windows and remediation SLAs tied directly to coverage terms. Several large brokers told AI Business Solutions that clients providing complete MAR bundles at placement typically experienced faster binding timelines; a number of broker anecdotes indicate low‑double‑digit premium reductions are achievable when MARs are combined with external attestations and clear remediation plans. Conversely, small vendors without registries or automated test pipelines continue to face longer underwriting cycles and loading for uncertainty.

"Structured MARs let us underwrite with evidence rather than speculation," said a senior underwriter at a global carrier. "That has reduced the need for broad exclusions and enabled more nuanced risk tiers tied to demonstrable controls."

"We required quarterly MAR exports from our cloud vendors as part of a new SLA; the development work paid off in faster placements and clearer renewal negotiations," said a head of procurement at a multinational healthcare firm, speaking on condition of anonymity.

Operational impact: procurement, legal and engineering

Procurement teams now embed MAR requirements into RFP templates and vendor master agreements; legal teams draft attestation language that defines scope, evidence retention and remediation SLAs linked to insurance conditions. Engineering teams prioritize "design for auditability": cryptographic signing of artifacts, automated test harnesses that produce structured outputs, and deployment gates that create verifiable approval records. Security teams are also working to ensure that telemetry needed for MARs is retained securely and complies with data protection obligations.

Costs, benefits and insurer perspective

Producing MARs carries upfront costs—registry adoption, evidence‑collection tooling and assurance fees—but insurers view these as reducing information asymmetry and disputed claims. For many enterprises the calculus now includes faster policy placement, clearer coverage language and improved negotiating leverage with cloud and model vendors that can provide signed artifacts. Insurers increasingly price on the presence and quality of MARs rather than treating AI as an unanalyzable black box.

Updated recommendations for enterprise teams (Oct. 2026)

  1. Map MAR fields to internal controls: Create a cross‑functional MAR template that links model metadata, test suites, governance evidence and telemetry to specific underwriting questions.
  2. Cryptographically anchor provenance: Use signed artifacts (hashes, certificate chains) so provenance can be independently verified by underwriters or third‑party auditors.
  3. Automate continuous testing with exportable outputs: Ensure adversarial, fairness and performance tests run in CI and produce versioned, machine‑readable results consumable by MAR bundles.
  4. Plan for retention and scope: Align evidence retention to business and regulatory needs (commonly 5–7 years for critical models) and scope attestations to a defined time window and dataset versions.
  5. Budget for external assurance where needed: For high‑risk models, include third‑party attestation fees and remediation budgets in insurance and deployment plans.

What to watch next

  • Whether a de‑facto MAR rubric emerges from a consortium of insurers, large brokers and cloud providers in late 2026 or early 2027.
  • How premium differentiation matures—will consistently documented models command materially lower premiums at scale?
  • Regulatory references to MAR‑like deliverables in sectoral guidance, particularly under the EU AI Act and financial‑sector regulators, over the next 12 months.

FAQ

Do all insurers require MARs now?

No. As of October 2026, a growing number of global carriers and major brokers routinely require MARs for high‑exposure accounts (financial services, healthcare and large cloud platforms). Regional carriers and smaller policies may still accept traditional questionnaires or attestations, but MAR requirements are expanding rapidly for higher‑risk use cases.

Can small vendors produce MARs without heavy engineering investment?

Yes—incremental steps help. Adopt a lightweight model registry, capture training and version metadata, run standardized test suites and produce clearly documented export bundles. Many third‑party tools and service providers offer low‑friction evidence collection; full automation improves underwriting outcomes but is not always required at the outset.

Will insurers accept third‑party attestations instead of a full MAR?

Insurers often accept qualified third‑party attestations, but attestations are most valuable when paired with machine‑readable artifacts that allow underwriters to benchmark and validate the claim. Scope, evidence chain and signature integrity matter—attestations should explicitly list the artifacts reviewed.

How should procurement update contracts today?

Include explicit MAR deliverables, timelines for attestations, remediation SLAs tied to insurance conditions, and requirements for vendor support in exporting required metadata and telemetry. Specify evidence retention periods and the form (machine‑readable, signed bundles) in renewal and exit clauses.

Machine‑readable MARs are no longer a theoretical compliance improvement: by October 2026 they are a practical part of enterprise insurance and procurement workflows. Teams that map engineering artifacts to underwriting questions, cryptographically anchor provenance and budget for assurance will shorten placement timelines and reduce commercial uncertainty.